Related Experiment Video
Updated: Oct 13, 2026

Handheld Metal Detector Screening for Metallic Foreign Body Ingestion in Children
Published on: September 11, 2018
Calcium channel blocker ingestions in children
M G Belson1, S E Gorman, K Sullivan
1Georgia Poison Center, Emory University School of Medicine, Atlanta, USA. Marty_Belson@oz.ped.emory.edu
Insights
Most pediatric calcium channel blocker (CCB) ingestions result in no or minor toxicity. Asymptomatic children ingesting small amounts of CCBs may be monitored at home, with specific observation times for sustained-release formulations.
Area of Science:
- Pediatric Toxicology
- Cardiovascular Pharmacology
- Poison Control Center Data Analysis
Background:
- Limited data exists on calcium channel blocker (CCB) toxicity in children.
- CCB ingestions are a concern for potential cardiovascular and central nervous system effects.
Purpose of the Study:
- Determine the frequency and range of toxicity from CCB ingestions in children.
- Establish appropriate observation times and assess effective interventions for pediatric CCB ingestions.
Main Methods:
- Retrospective review of 283 children younger than 7 years with CCB ingestions reported to a regional poison center over 6 years.
- Exclusion of patients with co-ingestants causing cardiovascular or CNS effects.
- Analysis of ingestion amounts, time to symptom onset, and clinical outcomes.
Main Results:
- Nifedipine, verapamil, and amlodipine were the most common CCBs ingested.
- 6% of patients experienced symptoms, including vomiting and CNS/cardiovascular effects.
- 74% of patients had no clinical effects; no deaths or major effects were reported.
Conclusions:
- Most pediatric CCB ingestions involve small amounts and result in minimal toxicity.
- Home monitoring may be appropriate for asymptomatic children ingesting specific amounts of sustained-release CCBs.
- Recommended observation periods are 3 hours for regular-release and 14 hours for sustained-release CCBs.
Unlabelled:
Limited data exists regarding toxicity of calcium channel blockers (CCBs) in children. The purpose of this study was to determine the frequency, the range of toxicity, the appropriate observation time, and to assess effective interventions for CCB ingestions in children. A 6-year retrospective review of CCB ingestions in children younger than 7 years of age reported to one regional poison center was undertaken. Patients with coingestants with recognized cardiovascular or central nervous system (CNS) effects were excluded. Two hundred eighty-three patients met criteria for review. The mean age was 27 months with 52% of all patients being boys. Nifedipine (38%), verapamil (34%), and amlodipine (14%) were most commonly ingested. Seventy-five percent of ingestions reportedly involved < or =1 pill. Symptoms occurred in 16/283 (6%): 4 had vomiting, and 12 had CNS or cardiovascular effects. The mean time to onset of symptoms for regular-release and for sustained-release (SR) CCB preparations were 1.5 hours (range 0.5 to 3 hr) and 4.5 hours (range 1 to 14 hr) respectively.
Outcome:
74% of patients had no clinical effects, 4% minor effects, 2% moderate effects, and 20% other. No deaths or major effects were reported.
Treatment:
88% of patients evaluated in an emergency department received gastric decontamination, usually one dose of charcoal. Calcium chloride was given in three verapamil SR cases. Five of six patients had reversal of hypotension with IV fluids and decontamination alone. Most pediatric CCB ingestions involve ingestions of small amounts of drug with no effects. Asymptomatic children in this study group who were known to have ingested <12 mg/kg of verapamil SR or <2.7 mg/kg of nifedipine SR could have been monitored at home. Of the children requiring evaluation and monitoring in a health care facility, an observation period for regular-release and SR-CCBs for 3 and 14 hours respectively would have been appropriate. There were insufficient cases with symptoms to draw conclusions for optimal therapeutic interventions.
Related Concept Videos
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Drug Dosing: Infants and Children
Drug Delivery: Enteral Route
Drugs in...